Annual Retained Earnings
$121.27 M
+$71.41 M+143.22%
31 December 2023
Summary:
Catalyst Pharmaceuticals annual retained earnings is currently $121.27 million, with the most recent change of +$71.41 million (+143.22%) on 31 December 2023. During the last 3 years, it has risen by +$174.98 million (+325.81%). CPRX annual retained earnings is now at all-time high.CPRX Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Retained Earnings
$229.22 M
+$43.88 M+23.68%
30 September 2024
Summary:
Catalyst Pharmaceuticals quarterly retained earnings is currently $229.22 million, with the most recent change of +$43.88 million (+23.68%) on 30 September 2024. Over the past year, it has increased by +$142.80 million (+165.22%). CPRX quarterly retained earnings is now at all-time high.CPRX Quarterly Retained Earnings Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
CPRX Retained Earnings Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +143.2% | +165.2% |
| 3 y3 years | +325.8% | +804.4% |
| 5 y5 years | +175.5% | +267.8% |
CPRX Retained Earnings High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +325.8% | at high | +804.4% |
| 5 y | 5 years | at high | +175.5% | at high | +267.8% |
| alltime | all time | at high | +175.5% | at high | +242.2% |
Catalyst Pharmaceuticals Retained Earnings History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $229.22 M(+23.7%) |
| June 2024 | - | $185.34 M(+28.2%) |
| Mar 2024 | - | $144.55 M(+19.2%) |
| Dec 2023 | $121.27 M(+143.2%) | $121.27 M(+40.3%) |
| Sept 2023 | - | $86.43 M(-26.3%) |
| June 2023 | - | $117.19 M(+47.5%) |
| Mar 2023 | - | $79.43 M(+59.3%) |
| Dec 2022 | $49.86 M(-289.5%) | $49.86 M(+104.4%) |
| Sept 2022 | - | $24.39 M(+1384.5%) |
| June 2022 | - | $1.64 M(-110.5%) |
| Mar 2022 | - | -$15.62 M(-40.6%) |
| Dec 2021 | -$26.31 M(-51.0%) | -$26.31 M(-19.2%) |
| Sept 2021 | - | -$32.54 M(-14.0%) |
| June 2021 | - | -$37.82 M(-18.4%) |
| Mar 2021 | - | -$46.34 M(-13.7%) |
| Dec 2020 | -$53.70 M(-58.3%) | -$53.70 M(-17.6%) |
| Sept 2020 | - | -$65.14 M(-40.0%) |
| June 2020 | - | -$108.48 M(-8.3%) |
| Mar 2020 | - | -$118.26 M(-8.1%) |
| Dec 2019 | -$128.69 M(-19.9%) | -$128.69 M(-5.8%) |
| Sept 2019 | - | -$136.62 M(-9.1%) |
| June 2019 | - | -$150.25 M(-6.8%) |
| Mar 2019 | - | -$161.21 M(+0.4%) |
| Dec 2018 | -$160.56 M(+26.9%) | -$160.56 M(+9.9%) |
| Sept 2018 | - | -$146.06 M(+5.7%) |
| June 2018 | - | -$138.23 M(+4.5%) |
| Mar 2018 | - | -$132.26 M(+4.5%) |
| Dec 2017 | -$126.56 M(+17.0%) | -$126.56 M(+4.4%) |
| Sept 2017 | - | -$121.17 M(+3.6%) |
| June 2017 | - | -$117.00 M(+3.4%) |
| Mar 2017 | - | -$113.12 M(+4.6%) |
| Dec 2016 | -$108.15 M(+20.1%) | -$108.15 M(+4.0%) |
| Sept 2016 | - | -$103.98 M(+4.0%) |
| June 2016 | - | -$100.03 M(+4.8%) |
| Mar 2016 | - | -$95.46 M(+6.0%) |
| Dec 2015 | -$90.08 M | -$90.08 M(+6.9%) |
| Sept 2015 | - | -$84.26 M(+5.6%) |
| June 2015 | - | -$79.81 M(+6.1%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2015 | - | -$75.25 M(+7.7%) |
| Dec 2014 | -$69.84 M(+28.5%) | -$69.84 M(+5.3%) |
| Sept 2014 | - | -$66.35 M(+8.2%) |
| June 2014 | - | -$61.34 M(+5.5%) |
| Mar 2014 | - | -$58.14 M(+7.0%) |
| Dec 2013 | -$54.33 M(+28.8%) | -$54.33 M(+2.6%) |
| Sept 2013 | - | -$52.98 M(+12.6%) |
| June 2013 | - | -$47.07 M(+7.2%) |
| Mar 2013 | - | -$43.92 M(+4.1%) |
| Dec 2012 | -$42.18 M(+10.7%) | -$42.18 M(+0.2%) |
| Sept 2012 | - | -$42.10 M(+6.6%) |
| June 2012 | - | -$39.48 M(+0.7%) |
| Mar 2012 | - | -$39.19 M(+2.9%) |
| Dec 2011 | -$38.10 M(+20.2%) | -$38.10 M(+6.6%) |
| Sept 2011 | - | -$35.75 M(+3.3%) |
| June 2011 | - | -$34.62 M(+4.2%) |
| Mar 2011 | - | -$33.23 M(+4.8%) |
| Dec 2010 | -$31.71 M(+14.5%) | -$31.71 M(+2.4%) |
| Sept 2010 | - | -$30.98 M(+3.0%) |
| June 2010 | - | -$30.08 M(+4.6%) |
| Mar 2010 | - | -$28.75 M(+3.8%) |
| Dec 2009 | -$27.71 M(+35.4%) | -$27.71 M(+4.4%) |
| Sept 2009 | - | -$26.54 M(+5.1%) |
| June 2009 | - | -$25.26 M(+7.5%) |
| Mar 2009 | - | -$23.49 M(+14.8%) |
| Dec 2008 | -$20.46 M(+106.7%) | -$20.46 M(+22.4%) |
| Sept 2008 | - | -$16.72 M(+20.6%) |
| June 2008 | - | -$13.86 M(+20.7%) |
| Mar 2008 | - | -$11.48 M(+16.0%) |
| Dec 2007 | -$9.90 M(+71.9%) | -$9.90 M(+10.6%) |
| Sept 2007 | - | -$8.95 M(+8.9%) |
| June 2007 | - | -$8.22 M(+17.2%) |
| Mar 2007 | - | -$7.01 M(+21.7%) |
| Dec 2006 | -$5.76 M(+90.1%) | -$5.76 M(+14.8%) |
| Sept 2006 | - | -$5.02 M(+35.7%) |
| June 2006 | - | -$3.70 M(+22.0%) |
| Dec 2005 | -$3.03 M(+147.5%) | -$3.03 M(+147.5%) |
| Dec 2004 | -$1.22 M | -$1.22 M |
FAQ
- What is Catalyst Pharmaceuticals annual retained earnings?
- What is the all time high annual retained earnings for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals annual retained earnings year-on-year change?
- What is Catalyst Pharmaceuticals quarterly retained earnings?
- What is the all time high quarterly retained earnings for Catalyst Pharmaceuticals?
- What is Catalyst Pharmaceuticals quarterly retained earnings year-on-year change?
What is Catalyst Pharmaceuticals annual retained earnings?
The current annual retained earnings of CPRX is $121.27 M
What is the all time high annual retained earnings for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high annual retained earnings is $121.27 M
What is Catalyst Pharmaceuticals annual retained earnings year-on-year change?
Over the past year, CPRX annual retained earnings has changed by +$71.41 M (+143.22%)
What is Catalyst Pharmaceuticals quarterly retained earnings?
The current quarterly retained earnings of CPRX is $229.22 M
What is the all time high quarterly retained earnings for Catalyst Pharmaceuticals?
Catalyst Pharmaceuticals all-time high quarterly retained earnings is $229.22 M
What is Catalyst Pharmaceuticals quarterly retained earnings year-on-year change?
Over the past year, CPRX quarterly retained earnings has changed by +$142.80 M (+165.22%)